Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Glenmark Pharmaceuticals S a patents


Recent patent applications related to Glenmark Pharmaceuticals S a. Glenmark Pharmaceuticals S a is listed as an Agent/Assignee. Note: Glenmark Pharmaceuticals S a may have other listings under different names/spellings. We're not affiliated with Glenmark Pharmaceuticals S a, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "G" | Glenmark Pharmaceuticals S a-related inventors


Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof for use in treating bone associated pain

The present invention relates to antibodies directed against TrkA receptor and their uses, including humanized anti-TrkA antibodies and methods of treatment with anti-TrkA antibodies.... Glenmark Pharmaceuticals S a

Expression constructs and methods for selecting host cells expressing polypeptides

The invention relates to an expression construct for the soluble expression of polypeptides in host cells and for the expression of polypeptides on the surface of host cells, using alternative splicing. The amount of cell membrane expression of polypeptides such as antibodies, antibody fragments and bispecific antibodies can be correlated... Glenmark Pharmaceuticals S a

Treatment of allergic rhinitis using a combination of mometasone and olopatadine

The present invention relates to a method of treating allergic rhinitis in a subject (e.g., a human) in need thereof comprising nasally administering to the subject an effective amount of a fixed-dose pharmaceutical composition comprising mometasone or its salt and olopatadine or its salt.... Glenmark Pharmaceuticals S a

Drug delivery device

Disclosed herein is a syringe device comprises (a) an outer housing, (b) a barrel, (c) a stopper, and (d) a plunger with one or more grooves.... Glenmark Pharmaceuticals S a

Antibodies that bind to ox40 and their uses

The present invention relates to antagonist antibodies or fragments thereof that bind to human OX40. More specifically, the present invention relates to an antagonist antibody or fragment thereof that binds to human OX40 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, and/or a... Glenmark Pharmaceuticals S a

Novel compounds as ror gamma modulators

The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, ring B, L, R1, R2, R3, R4, R5, Ra, Rb, n, m, p and q are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (RORγt). These... Glenmark Pharmaceuticals S a

Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof

The present invention relates to antibodies directed against TrkA receptor and their uses, including humanized anti-TrkA antibodies. More specifically, the present invention relates to humanized anti-TrkA antibodies with enhanced inhibitory properties comprising a heavy chain variable region, a light chain variable region, a human light chain constant region and a... Glenmark Pharmaceuticals S a

Production of t cell retargeting hetero-dimeric immunoglobulins

The present invention describes novel hetero-dimeric immunoglobulins or fragments thereof which bind to CD3 and a disease associated antigen. These hetero-dimeric immunoglobulins have been engineered to promote hetero-dimer formation during expression and can be purified to a high degree using a Protein A differential purification technique.... Glenmark Pharmaceuticals S a

Nanoparticulate formulation comprising a mpges-1 inhibitor

The present invention relates to a nanoparticulate formulation comprising a microsomal prostaglandin E synthases-1 (“mPGES-1”) inhibitor. Particularly, the present invention relates to a nanoparticulate formulation comprising an mPGES-1 inhibitor and one or more surface stabilizers; a process for preparing such formulation; and its use in treating pain and inflammation in... Glenmark Pharmaceuticals S a

Aryl and heteroaryl ether compounds as ror gamma modulators

The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein Ring A, Ring B, R, R2, R3, n, and p are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (RORγt). These compounds prevent, inhibit, or suppress the action... Glenmark Pharmaceuticals S a








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Glenmark Pharmaceuticals S a in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Glenmark Pharmaceuticals S a with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###